Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on September 27, 2024 and one Late Breaking Clinical Trial presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place September 27-30, 2024, both in Atlanta, GA.
2024 HCMS Scientific Sessions
Oral Abstract Presentation
Title: Global Remodeling Changes with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Analysis of the SEQUOIA-HCM Trial
Presenter: Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania
Date: September 27, 2024
Session Title: Oral Abstract Presentations
Session Time: 11:00 – 12:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
Poster Abstract Presentation
Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Very High Left Ventricular Outflow Tract Gradients
Presenter: Juan R. Gimeno, M.D., Consultant Cardiologist, Hospital Universitario Virgen de la Arrixaca, Associate Professor, Medicine – Cardiology, Universidad de Murcia, Spain
Date: September 27, 2024
Session Title: Closing Remarks & Poster Cocktail Reception
Session Time: 4:00 – 5:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
Title: Beta-Blocker Use and Incidence of New Atrial Fibrillation or Flutter Requiring Therapy in Post-Septal Myectomy Hypertrophic Cardiomyopathy Patients
Presenter: Morris M. Kim, M.D., Cardiovascular Disease Fellow, Oregon Health & Science University
Date: September 27, 2024
Session Title: Closing Remarks & Poster Cocktail Reception
Session Time: 4:00 – 5:00 PM ET
Location: Signia by Hilton, Atlanta Georgia World Congress Center
HFSA Annual Scientific Meeting
Title: Global Clinical Impact of Aficamten in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center
Date: September 30, 2024
Session Title: Plenary Sessions - Monday Plenary Session: Late Breaking Clinical Research Session II
Session Time: 9:00 – 10:30 AM ET
Presentation Time: 9:20 – 9:28 AM ET
Location: Georgia World Congress Center - Georgia Ballroom 2
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy which were published in the New England Journal of Medicine. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics, visit and follow us on , , and .
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
